NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

MIST

Milestone Pharmaceuticals Inc

Jul 03 • 04:00PM ET

1.94

Dollar change +0.02
Percentage change 1.04	%

Healthcare • Biotechnology • Canada • NASD

Peers: ACAD BPMC FGEN RARE XENE BHVN AXSM VTGN IKT

| Held by: SURI GWX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.83	Insider Own	1.06%	Shs Outstand	53.46M	Perf Week	0.00%
Market Cap	103.72M	Forward P/E	-	EPS next Y	-0.86	Insider Trans	0.00%	Shs Float	52.90M	Perf Month	14.79%
Enterprise Value	103.35M	PEG	-	EPS next Q	-0.18	Inst Own	22.24%	Short Float	3.80%	Perf Quarter	141.56%
Income	-51.93M	P/S	-	EPS this Y	-21.89%	Inst Trans	-40.72%	Short Ratio	1.81	Perf Half Y	-13.78%
Sales	0.00M	P/B	-	EPS next Y	-4.90%	ROA	-65.78%	Short Interest	2.01M	Perf YTD	-17.80%
Book/sh	-0.11	P/C	1.85	EPS next 5Y	9.29%	ROE	-307.27%	52W High	2.75 -29.45%	Perf Year	44.78%
Cash/sh	1.05	P/FCF	-	EPS past 3/5Y	13.31% 28.21%	ROIC	-106.14%	52W Low	0.63 210.20%	Perf 3Y	-68.35%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.08% 5.24%	Perf 5Y	-49.61%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	38.02%	Oper. Margin	-	ATR (14)	0.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.67	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	65.73	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	4.67	EPS Q/Q	-51.74%	SMA20	8.38%	Beta	0.54	Target Price	4.50
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	27.00%	Rel Volume	0.21	Prev Close	1.92
Employees	33	LT Debt/Eq	-	Earnings	May 14 BMO	SMA200	16.03%	Avg Volume	1.11M	Price	1.94
IPO	May 09, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-67.57% -	Trades		Volume	237,742	Change	1.04%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-25	Resumed	H.C. Wainwright	Buy	$5
Aug-22-24	Initiated	Rodman & Renshaw	Buy	$9
Jun-20-23	Downgrade	Jefferies	Buy → Hold	$8 → $4
Apr-22-22	Upgrade	Piper Sandler	Neutral → Overweight	$8 → $10
Mar-05-21	Initiated	H.C. Wainwright	Buy	$20
Jul-29-20	Upgrade	Oppenheimer	Perform → Outperform	$18
Jul-24-20	Upgrade	Jefferies	Hold → Buy
Mar-25-20	Downgrade	Jefferies	Buy → Hold	$28 → $3
Mar-24-20	Downgrade	Piper Sandler	Overweight → Neutral	$26.50 → $3
Mar-24-20	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-19	Initiated	Oppenheimer	Outperform	$32
Jun-03-19	Initiated	Piper Jaffray	Overweight	$26.50
Jun-03-19	Initiated	Jefferies	Buy	$28
Jun-03-19	Initiated	Cowen	Outperform	$32

Show Previous Ratings

Jun-16-25 08:00AM	Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting (GlobeNewswire)
May-28-25 08:00AM	Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.04%
May-22-25 12:00PM	Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why (Zacks)
May-14-25 07:22AM	Milestone Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:04AM	Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
10:26AM	Loading…
Apr-09-25 10:26AM	Milestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVT (Seeking Alpha) +10.78%
Apr-04-25 02:30PM	Stock Picks From Seeking Alpha's March 2025 New Analysts (Seeking Alpha) -7.24%
Apr-02-25 03:00PM	MIST Stock Falls 66% Following Complete Response Letter for Cardamyst (Zacks) +5.67%
08:37AM	Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen (TipRanks)
Apr-01-25 03:48PM	TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty (Investing.com) -5.01%
Mar-29-25 12:00PM	Milestone CRL affirms integrity of clinical data, says H.C. Wainwright (TipRanks)
Mar-28-25 07:00AM	FDA Issues Complete Response Letter for Etripamil for PSVT (GlobeNewswire) -60.89%
Mar-21-25 03:18PM	Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers (SeekingAlpha)
Mar-20-25 08:00AM	Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology (GlobeNewswire)
Mar-13-25 07:32AM	Milestone Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance) +5.18%
07:08AM	Loading…
07:08AM	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
Mar-04-25 08:00AM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 08:00AM	Milestone Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-19-25 08:00AM	Milestone Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil (GlobeNewswire)
Feb-11-25 08:00AM	Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025 (GlobeNewswire)
Jan-28-25 08:00AM	Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC (GlobeNewswire)
Jan-07-25 08:00AM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-25-24 08:00AM	Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-19-24 09:55AM	After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright (Zacks)
Nov-12-24 09:17AM	Milestone Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
09:03AM	Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
Sep-24-24 08:00AM	Milestone Pharmaceuticals to Host Investor KOL Event (GlobeNewswire)
Sep-06-24 07:00AM	Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China (GlobeNewswire)
Sep-04-24 08:00AM	Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors (GlobeNewswire) +7.19%
Sep-03-24 08:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
08:00AM	Loading…
Aug-26-24 08:00AM	Milestone Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024 (GlobeNewswire)
Aug-08-24 04:41PM	Milestone Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance) +6.02%
04:17PM	Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
Jul-31-24 08:00AM	Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-15-24 08:00AM	Milestone Pharmaceuticals Refreshes Board of Directors (GlobeNewswire)
Jun-12-24 08:00AM	Milestone Pharmaceuticals to Host KOL Event for Investors Learnings from the Field: Expert Perspectives on PSVT in the Community Setting on June 20, 2024 (GlobeNewswire)
May-31-24 08:00AM	Milestone Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-24 07:00AM	Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST (GlobeNewswire) -5.45%
May-22-24 08:00AM	Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness (GlobeNewswire)
May-16-24 12:00PM	Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know (Zacks)
May-13-24 01:53PM	MIST Stock Earnings: Milestone Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
07:15AM	Milestone Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:15AM	Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
May-02-24 08:00AM	Milestone Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024 (GlobeNewswire)
Apr-17-24 08:00AM	Milestone Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium (GlobeNewswire)
Apr-08-24 11:36AM	Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting (GlobeNewswire)
Apr-03-24 08:00AM	Milestone Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference (GlobeNewswire)
Apr-01-24 08:00AM	Milestone Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences (GlobeNewswire)
Mar-28-24 07:00AM	Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia (GlobeNewswire)
Mar-21-24 01:53PM	MIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace)
07:14AM	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
Feb-29-24 04:01PM	Milestone Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference (GlobeNewswire) -21.13%
07:00AM	Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants (GlobeNewswire)
Feb-28-24 04:37PM	Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants (GlobeNewswire)
Feb-26-24 07:00AM	Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT (GlobeNewswire) +24.12%
Jan-18-24 01:23PM	Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations: Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire)
Jan-16-24 09:35AM	Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround (Zacks)
Dec-27-23 11:11AM	Milestone Pharma (MIST) Down on Regulatory Update for Etripamil (Zacks) -5.53%
Dec-26-23 10:55AM	Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire) -30.90%
07:00AM	Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT (GlobeNewswire)
Nov-21-23 07:00AM	Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference (PR Newswire) +13.16%
Nov-13-23 07:02AM	Milestone Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) -19.59%
06:57AM	Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates (PR Newswire)
Nov-11-23 10:00AM	Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023 (PR Newswire)
Nov-07-23 07:00AM	Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR (PR Newswire)
Oct-24-23 07:00AM	Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil (PR Newswire)
Oct-06-23 07:00AM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-27-23 07:00AM	Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023 (PR Newswire)
Sep-05-23 07:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-10-23 07:56AM	Milestone Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance) +5.77%
07:35AM	Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update (PR Newswire)
Aug-08-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks) +17.63%
Jun-20-23 07:00AM	Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet (PR Newswire)
Jun-10-23 09:40AM	Individual investors account for 48% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 38% (Simply Wall St.)
Jun-01-23 07:00AM	Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference (PR Newswire) -6.09%
May-22-23 07:00AM	Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate (PR Newswire)
May-11-23 07:31AM	Milestone Pharmaceuticals: Q1 Earnings Snapshot (AP Finance) +8.97%
07:16AM	Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update (PR Newswire)
May-08-23 07:00AM	Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate (PR Newswire) +9.19%
May-01-23 06:02AM	Lorenz Muller Is The Chief Commercial Officer of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) And They Just Picked Up 23% More Shares (Simply Wall St.)
Apr-21-23 09:23AM	Milestone Pharmaceuticals' (NASDAQ:MIST) investors will be pleased with their decent 75% return over the last three years (Simply Wall St.)
Apr-12-23 07:00AM	Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-31-23 10:39AM	Despite recent gains, Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insiders are still down US$91k after purchasing last year (Simply Wall St.)
Mar-29-23 09:17AM	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update (PR Newswire)
Mar-28-23 07:00AM	Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT (PR Newswire) +10.83%
Mar-06-23 07:00AM	Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia (PR Newswire) +12.23%
Feb-28-23 07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences (PR Newswire)
Jan-16-23 12:00PM	Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why (Zacks)
Jan-01-23 08:33AM	Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is definitely on the radar of institutional investors who own 33% of the company (Simply Wall St.)
Dec-13-22 09:35AM	Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks (Zacks)
Dec-02-22 02:11PM	Will Milestone Pharmaceuticals (NASDAQ:MIST) Spend Its Cash Wisely? (Simply Wall St.)
Nov-29-22 07:00AM	Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT (PR Newswire)
Nov-22-22 07:00AM	Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference (PR Newswire)
Nov-12-22 07:47AM	Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have unfortunately lost 74% over the last three years (Simply Wall St.)
Nov-10-22 07:21AM	Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update (PR Newswire) +9.54%
Nov-07-22 12:13PM	Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022 (PR Newswire) -10.32%
Oct-25-22 07:00AM	Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022 (PR Newswire) +8.28%
Oct-22-22 08:21AM	Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) recent US$101m market cap decline means a loss of US$6.2k for insiders who bought this year (Simply Wall St.)
08:05AM	Independent Non-Executive Director Michael Tomsicek Just Bought A Handful Of Shares In Milestone Pharmaceuticals Inc. (NASDAQ:MIST) (Simply Wall St.)
Oct-20-22 09:35AM	Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 42.9% in 4 Weeks (Zacks) +5.44%

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MIST

Milestone Pharmaceuticals Inc

Upgrade your FINVIZ experience